Trial reportInflammopharmacology2026
Comparative efficacy of transdermal buprenorphine versus diclofenac in the management of knee osteoarthritis: a randomized controlled trial with network pharmacology insights.
Trial report in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoarthritis (OA) is a degenerative joint disease, which is accompanied by chronic pain and functional impairment, especially among the elderly population. Transdermal drug delivery offers a non-invasive option for managing OA. Our study assesses the relative effectiveness and safety of transdermal Buprenorphine compared to Diclofenac patches in the treatment of knee OA. RESEARCH DESIGN AND
methodsA randomized controlled trial was performed in 152 patients with radiographically confirmed Grade I/II knee OA and with an age of 50 years and above. The participants were divided into two groups: Group A (transdermal buprenorphine) and Group B (transdermal diclofenac) as the treatment options to be used within 4 weeks. The Numeric Rating Scale (NRS), Western Ontario and McMaster Universities Arthritis Index (WOMAC), and Lequesne Index were used to measure pain intensity, functional status, and disease severity, respectively. Network pharmacology analysis was also used to examine additional interactions such as safety, treatment compliance and molecular interactions.
resultsBoth treatments reduced pain significantly as well as improved functional outcomes. Nevertheless, buprenorphine had a higher clinical efficacy with higher reductions in NRS scores (7.72 to 2.81 vs. 7.68 to 3.23), WOMAC total scores (71.5 to 31.8 vs. 74.0 to 45.6), and Lequesne Index values (17.4, to 5.87 vs. 17.3, to 8.42) than diclofenac. Network pharmacology analysis revealed that buprenorphine modulates 25 genes related to OA, while diclofenac affects 20 genes, suggesting that Buprenorphine may have a wider range of benefits. Both treatments demonstrated excellent tolerability.
conclusionsTransdermal buprenorphine was found to have better short-term analgesic and functional advantages than transdermal diclofenac in early-stage knee OA. Its high tolerability, once-weekly topography and broad-spectrum interactions with its molecular targets justify its possible use in the treatment of a discrete group of patients, specifically older healthcare individuals or those intolerant to NSAIDs.
Indexed as
Identifiers
41770501What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.